Eli Lilly (LLY) heads into 2026 with GLP-1 pricing and competition risks; oral GLP-1 race heats up and downside looms.

Novo Nordisk shares have surged on the back of its groundbreaking oral Wegovy approval, making it the first company to bring ...

Techs lead futures Friday but after Thursday's market fade. AMD is eyeing an early buy point again on Taiwan Semiconductor ...

True, Novo Nordisk is making progress in this field. It recently earned approval for an oral formulation of Wegovy, which ...

Although the stock is trading at a premium valuation, the company’s outstanding operational performance, strong financial ...

Novo Nordisk's Wegovy pill hit 3,071 U.S. prescriptions in the first four days after its launch, IQVIA data shared by ...

Nurix advances CLL therapy with NX-5948 showing 83% response, 22.1-month PFS, $680M cash, and $3B risk-adjusted sales ...

Join us as we explore Eli Lilly's impressive market position and financial health. Discover why this pharmaceutical giant is ...